These guidelines have been developed by NHMRC on advice from its Animal Welfare Committee to promote the wellbeing of animals used for scientific purposes and aim to minimise their experience of pain and distress. They advocate the consideration of an animal's "whole of life" experiences, argue the potential risk to the reliability/validity of research data from unintended pain or distress, and promote the 3R's (replacement of animal research with other types of research when possible, reduction of the number of animals used in research and refinement of research techniques to minimise pain and distress).

The National Quality Use of Medicines Indicators for Australian Hospitals (National QUM Indicators) is a set of process indicators developed for Australian hospitals and health professionals. 

As part of the initiative to have more efficient research governance processes, NHMRC and the Therapeutic Goods Administration (TGA) are working to achieve a safety reporting system that is efficient and reflects contemporary reporting requirements.

To improve clinical trial start-up times, following extensive stakeholder consultation and under the guidance and leadership of the NHMRC Research Governance Working Group, NHMRC has developed the Good Practice Process for Site Assessment and Authorisation Phases of Clinical Trial Research Governance (the Good Practice Process).

This resource is to complement your learning, and introduce you to other perspectives on the topics under discussion.

These guidelines have been developed by NHMRC on advice from its Animal Welfare Committee to promote the wellbeing of animals used for scientific purposes and aim to minimise their experience of pain and distress. They advocate the consideration of an animal's "whole of life" experiences, argue the potential risk to the reliability/validity of research data from unintended pain or distress, and promote the 3R's (replacement of animal research with other types of research when possible, reduction of the number of animals used in research and refinement of research techniques to minimise pain and distress).

This resource is to complement your learning, and introduce you to other perspectives on the topics under discussion.

The National Quality Use of Medicines Indicators for Australian Hospitals (National QUM Indicators) is a set of process indicators developed for Australian hospitals and health professionals. 

In 2013, the Victorian, South Australian and Queensland Departments of Health, and the New South Wales Ministry of Health signed a Memorandum of Understanding (MOU) for the National Mutual Acceptance (NMA) of ethics and scientific review of clinical trials conducted in each of the participating jurisdictions’ public health organisations. In December 2015, the scope of NMA was expanded beyond clinical trials to include all human research. In August 2016, the Australian Capital Territory joined the NMA and Western Australia will join in August 2017.

As part of the initiative to have more efficient research governance processes, NHMRC and the Therapeutic Goods Administration (TGA) are working to achieve a safety reporting system that is efficient and reflects contemporary reporting requirements.

This Chapter presents the revised List of standard items associated with the conduct of clinical trials. To put the List into context, it starts with a series of principles that should guide the use of the List, and a summary of the structure of the List. The full set of items in the revised List with proposed definitions is then presented. 

To improve clinical trial start-up times, following extensive stakeholder consultation and under the guidance and leadership of the NHMRC Research Governance Working Group, NHMRC has developed the Good Practice Process for Site Assessment and Authorisation Phases of Clinical Trial Research Governance (the Good Practice Process).